New England Journal of Medicine publishes long-term results of Gleevec for patients with chronic myeloid leukemia
In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec, as an oral therapy for patients with chronic myeloid leukemia, or CML.
Mar 9, 2017